# Turenne Groupe

> Turenne Groupe is a VC fund in Paris backing Biotechnology, Medical and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Paris, France
- Total investments: 5
- Last investment: Dec 2024
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/turenne-capital/
- X (Twitter): https://twitter.com/turenne_capital
- Website: https://www.turennecapital.com/?lang=en

Turenne Groupe is a private equity firm focusing on healthcare, hotels, innovative industry, and ecotechnology industry.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Medical | 2 | 40% |
| Health Care | 2 | 40% |
| Art | 1 | 20% |
| Internet | 1 | 20% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Series B | 2 | 40% |
| Venture - Series Unknown | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 4 | 80% |
| Switzerland | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| DeepLife | DeepLife uses deep learning on multi-omics data to model cells and efficiently engineer their behavior.DeepLife is a biotech company with a mission to build the next generation of system biology. The company works in a highly collaborative translational manner, to facilitate the transition of discoveries from the laboratory to patients. Thecompany operates through collaboration with academic groups in their respective areas of expertise. | $10M | Series A | Dec 11, 2024 |  |
| SamanTree Medical | SamanTree Medical is a swiss innovative medical device company providing a breakthrough imaging solution with the potential to improve patient care and cancer surgery outcome. Based on confocal microscopy, SamanTree Medical’s solution brings accurate and full margin control by the surgeon, in the operating room. | $14M | Series B | Jul 16, 2024 |  |
| AbolerIS Pharma | AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance. | $29.2M | Series A | Sep 18, 2023 |  |
| Singulart | At Singulart, They are convinced that the digital space is an invaluable tool for bringing transparency and equity to the art market.They provide artists with the tools that enable them to independently manage the sale of their works. Their team is working around the clock, committing their energy to promoting Singulart artists to a globalaudience.In showcasing artists around the world, they also hope to allow art lovers and collectors alike to explore new artistic horizons, to embrace new cultures and to be inspired by the works of talented artists that they never would have come across if it wasn't for Singulart. | $67.7M | Series B | Nov 19, 2021 |  |
| Naturopéra | NATUROPERA's vision is therefore to help change consumption to restore the balance of life. compositions and formulations respectful of the environment. | $4.6M | Venture - Series Unknown | Oct 06, 2021 |  |

5 of 5 investments shown.

## Co-investors
- [Relyens](https://shizune.co/investors/profile/relyens) — VC Fund, 2 deals together
- [Beiersdorf](https://shizune.co/investors/profile/beiersdorf) — VC Fund, 1 deal together
- [BOM Brabant Ventures](https://shizune.co/investors/profile/bom-brabant-ventures) — VC Fund, 1 deal together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 1 deal together
- [b2venture](https://shizune.co/investors/profile/btovpartners) — VC Fund, 1 deal together
- [Criteria Venture Tech](https://shizune.co/investors/profile/caixa-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Turenne Groupe invest in?

Turenne Groupe invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Turenne Groupe last invest?

The most recent investment recorded for Turenne Groupe closed in Dec 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co